Suchergebnisse - "Lauseker, Michael"

PubPharm (14)

1

Survival with chronic myeloid leukaemia after failing milestones

enthalten in: Leukemia | 2023

von Lauseker, M. | Hehlmann, R. | Hochhaus, A. | +1

CommentIn: Leukemia. 2023 Oct 5;:. - PMID 37798329

2

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

enthalten in: Leukemia | 2020

von Pfirrmann, M. | Clark, R. | Prejzner, W. | +27

3

Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex : Results from a population-based study

enthalten in: European journal of haematology | 2019

von Lauseker, M. | Gerlach, R. | Worseg, W. | +4

4

The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance

enthalten in: Endocrine-related cancer | 2018

von Aristizabal Prada, E. | Spöttl, G. | Maurer, J. | +8

5

The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors : Results from multiple cell line models

enthalten in: PloS one | 2017

von Nölting, S. | Rentsch, J. | Freitag, H. | +15

6

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death

enthalten in: Annals of hematology | 2015

von Pfirrmann, M. | Lauseker, M. | Hoffmann, V. | +1

7

Reply to H. Kantarjian et al

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hehlmann, R. | Hasford, J. | Pfirrmann, M. | +5

CommentOn: J Clin Oncol. 2014 Feb 10;32(5):415-23. - PMID 24297946

8

Remission status should not be treated as a base-line covariate--reply to Etienne et al

enthalten in: Haematologica | 2014

von Lauseker, M. | Hasford, J.

CommentOn: Haematologica. 2014 Mar;99(3):458-64. - PMID 24362549

9

Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients : a subanalysis of the randomized CML-Study IV

enthalten in: Annals of hematology | 2014

von Proetel, U. | Pletsch, N. | Lauseker, M. | +124

10

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib : results from the randomized CML-study IV

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hehlmann, R. | Müller, M. | Lauseker, M. | +29

CommentIn: J Clin Oncol. 2014 Feb 10;32(5):471-4. - PMID 24297955